Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Debt to Equity (2016 - 2024)

Protalix BioTherapeutics has reported Debt to Equity over the past 11 years, most recently at $0.71 for Q2 2024.

  • Quarterly results put Debt to Equity at $0.71 for Q2 2024, changed N/A from a year ago — trailing twelve months through Jun 2024 was $0.71 (changed N/A YoY), and the annual figure for FY2023 was $0.6, changed.
  • Debt to Equity for Q2 2024 was $0.71 at Protalix BioTherapeutics, up from $0.69 in the prior quarter.
  • Over the last five years, Debt to Equity for PLX hit a ceiling of $15.21 in Q3 2021 and a floor of -$2.01 in Q4 2020.
  • Median Debt to Equity over the past 4 years was $0.7 (2024), compared with a mean of $4.28.